Exact Sciences CorporationEXASNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

businesswire.com

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri.

defenseworld.net

Bridgefront Capital LLC Buys Shares of 11,994 Exact Sciences Corporation $EXAS

Bridgefront Capital LLC bought a new position in Exact Sciences Corporation (NASDAQ: EXAS) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 11,994 shares of the medical research company's stock, valued at approximately $656,000. Several other institutional investors have also recently made changes to their

defenseworld.net

ArrowMark Colorado Holdings LLC Purchases 113,603 Shares of Exact Sciences Corporation $EXAS

ArrowMark Colorado Holdings LLC boosted its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 23.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 597,931 shares of the medical research company's stock after purchasing an additional 113,603 shares during the

defenseworld.net

Exact Sciences Corporation $EXAS Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 12.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,188,864 shares of the medical research company's stock after buying an additional 239,313 shares

zacks.com

Exact Sciences (EXAS) is a Top-Ranked Momentum Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com

CSLLY or EXAS: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Exact Sciences (EXAS). But which of these two stocks presents investors with the better value opportunity right now?

businesswire.com

Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive year the company has received this prestigious recognition. The award honors organizations with some of the most engaged workplace cultures in the world. Gallup recognized Exact Sciences for fostering a culture where employees feel valued and connected to t.

businesswire.com

Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

WILMINGTON, Del.--(BUSINESS WIRE)-- #AIinHealthcare--Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ: EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rat.

defenseworld.net

DNB Asset Management AS Raises Position in Exact Sciences Corporation $EXAS

DNB Asset Management AS boosted its position in Exact Sciences Corporation (NASDAQ: EXAS) by 15.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 246,639 shares of the medical research company's stock after purchasing an additional 33,071 shares

businesswire.com

Exact Sciences Stockholders Approve Acquisition by Abbott

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie.

zacks.com

Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com

Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up

EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress.

defenseworld.net

Aberdeen Group plc Increases Stock Position in Exact Sciences Corporation $EXAS

Aberdeen Group plc raised its holdings in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 52.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 304,609 shares of the medical research company's stock after acquiring an additional 105,138 shares during the quarter.

gurufocus.com

Paul Tudor Jones Makes Significant Moves with iShares Core S&P 500 ETF

Exploring the Latest 13F Filing and Investment Strategies Paul Tudor Jones (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025

zacks.com

CSLLY vs. EXAS: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?

gurufocus.com

George Soros Reduces Stake in Smurfit WestRock PLC by 68.99%

Insight into Soros's Strategic Moves in Q4 2025 George Soros (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providing in

defenseworld.net

Exact Sciences Corporation $EXAS Shares Sold by AlphaQuest LLC

AlphaQuest LLC cut its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 89.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 898 shares of the medical research company's stock after selling 7,641 shares during the

seekingalpha.com

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.

zacks.com

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.06 per share a year ago.

gurufocus.com

Market Today: AI Fears Rattle Stocks; CPI Cools, Rivian Pops

Guru Stock PicksRobert Bruce has made the following transactions:Reduce in NEE by 1.49%Ray Dalio has made the following transactions:Reduce in CNX by 13.43%Sold

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance